Early access to medicines scheme (EAMS) scientific opinion: Atezolizumab for locally advanced or metastatic urothelial carcinoma
This publication was withdrawn on
The EAMS opinion for atezolizumab for locally advanced or metastatic urothelial carcinoma has expired as a marketing authorisation has been granted to a similar medicine covering the EAMS indication. As some patients may still be on treatment, the safety information in the Treatment Protocol have been updated on 19 June 2017. Contact information regarding queries on the use of this EAMS medicine can be found at the end of this document.
EAMS scientific opinion given to Atezolizumab to treat locally advanced or metastatic urothelial carcinoma, including the public assessment report.